OmniAb Showcases xPloration Platform at PEGS Boston to Transform Antibody Discovery with AI-Powered Single B-Cell Screening

14 May 2025 | Wednesday | News

With high-throughput precision and machine learning integration, xPloration enables rapid, deep mining of immunized repertoires—accelerating partner discovery programs and now available for in-lab use via the new Partner Access Program.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

xPloration Maximizes Impact for OmniAb’s Partners through Efficient and Precise Mining of Immunized Antibody Repertoires

OmniAb, Inc.  announced its participation in the 21st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial intelligence (AI), in a presentation by Bob Chen, Ph.D., Vice President, Discovery Systems, titled “xPloration: Simplifying Deep Antibody Mining for Maximum Impact.”

“Thorough mining of primary B-cells from immunized animals presents a major challenge in therapeutic antibody discovery. Traditional methods often restrict antibody diversity and require weeks to complete. In contrast, the xPloration platform processes millions of single B-cells and recovers thousands of antibody variants within hours, achieving impactful results,” said Dr. Chen. “By enabling deep mining of immunized repertoires with flexible assays, xPloration excels at rare hit selection, large repertoire analysis, and screening for various targets including membrane proteins. It is an integral part of our discovery engine, and our validated workflow for all OmniAb animals ensures precision and efficiency in partner discovery projects.”

xPloration boosts the effectiveness of discovery programs by screening 10 times more single cells per day than other spatial separation techniques. Its laser-based recovery process enables the sorting of thousands of live cells through a “touchless” method. With short instrument run times of approximately 1.5 hours, it allows for the rapid completion of a screening campaign. In addition to enhancing speed, xPloration’s fluidics-free system improves reliability and AI-assisted image analysis provides ease-of-use.

Building on this, today’s presentation illustrated the platform’s capabilities across various assay formats, including multiplex cell surface binding and cross-blocking assays. These flexible xPloration assays can unlock the specific antibody profiles partners are looking for. The presentation also demonstrated synergy between OmniAb’s animal platforms and xPloration screening to enable deep repertoire mining.

Last week, OmniAb launched the Partner Access Program for xPloration, under which current OmniAb partners can purchase the instrument for use within their own laboratories.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close